UA115079C2 - Сполуки як інгібітори діацилгліцеринацилтрансферази - Google Patents

Сполуки як інгібітори діацилгліцеринацилтрансферази

Info

Publication number
UA115079C2
UA115079C2 UAA201506216A UAA201506216A UA115079C2 UA 115079 C2 UA115079 C2 UA 115079C2 UA A201506216 A UAA201506216 A UA A201506216A UA A201506216 A UAA201506216 A UA A201506216A UA 115079 C2 UA115079 C2 UA 115079C2
Authority
UA
Ukraine
Prior art keywords
novel compounds
diacylglycerol acyltransferase
dgat
acyltransferase inhibitors
inhibitors
Prior art date
Application number
UAA201506216A
Other languages
English (en)
Inventor
Муй Чеун
Рагурам С. Тангірала
Original Assignee
Глаксосмітклайн Ллс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Глаксосмітклайн Ллс filed Critical Глаксосмітклайн Ллс
Publication of UA115079C2 publication Critical patent/UA115079C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Epidemiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Даний винахід стосується нових сполук, які є інгібіторами ацилкоферменту А: діацилгліцеринацилтрансферази 1 (ДГАТ-1), фармацевтичних композицій, що містять їх, способів їх отримання та їх застосування в терапії, окремо або у поєднанні з терапіями по корекції маси тіла або іншими терапіями по зниженню тригліцеридів, або для лікування захворювань, пов'язаних з дисфункцією ДГАТ-1 або в яких модулювання активності ДГАТ-1 може надати терапевтичну дію.
UAA201506216A 2012-11-23 2013-11-22 Сполуки як інгібітори діацилгліцеринацилтрансферази UA115079C2 (uk)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN3593DE2012 2012-11-23
IN750DE2013 2013-03-14
IN3172DE2013 2013-10-25
PCT/US2013/071376 WO2014081994A1 (en) 2012-11-23 2013-11-22 Novel compounds as diacylglycerol acyltransferase inhibitors

Publications (1)

Publication Number Publication Date
UA115079C2 true UA115079C2 (uk) 2017-09-11

Family

ID=50776577

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201506216A UA115079C2 (uk) 2012-11-23 2013-11-22 Сполуки як інгібітори діацилгліцеринацилтрансферази

Country Status (31)

Country Link
US (1) US20150322082A1 (uk)
EP (2) EP3492474B1 (uk)
JP (1) JP6279600B2 (uk)
KR (1) KR102176463B1 (uk)
CN (1) CN104918620B (uk)
AU (1) AU2013347843B2 (uk)
BR (1) BR112015011982A8 (uk)
CA (1) CA2892304C (uk)
CL (1) CL2015001397A1 (uk)
CY (1) CY1121426T1 (uk)
DK (1) DK2922551T3 (uk)
EA (1) EA031114B1 (uk)
ES (1) ES2708626T3 (uk)
HK (1) HK1214757A1 (uk)
HR (1) HRP20190099T1 (uk)
HU (1) HUE042483T2 (uk)
IL (1) IL238835B (uk)
LT (1) LT2922551T (uk)
ME (1) ME03315B (uk)
MX (1) MX363484B (uk)
NZ (1) NZ630436A (uk)
PE (1) PE20150967A1 (uk)
PH (1) PH12015501109A1 (uk)
PL (1) PL2922551T3 (uk)
PT (1) PT2922551T (uk)
RS (1) RS58539B1 (uk)
SG (1) SG11201503761WA (uk)
SI (1) SI2922551T1 (uk)
UA (1) UA115079C2 (uk)
WO (1) WO2014081994A1 (uk)
ZA (1) ZA201503304B (uk)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018052818A (ja) * 2015-01-28 2018-04-05 武田薬品工業株式会社 スルホンアミド化合物
MA46859A (fr) * 2016-11-18 2019-09-25 Merck Sharp & Dohme Dérivés d'indole utiles en tant qu'inhibiteurs de la diacylglycéride o-acyltransférase 2

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100795462B1 (ko) * 2006-09-27 2008-01-16 한국생명공학연구원 인돌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 대사성 질환 예방 및 치료용 약학적 조성물
US20090036425A1 (en) * 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
US20090076275A1 (en) * 2007-09-19 2009-03-19 David Robert Bolin Diacylglycerol acyltransferase inhibitors
AR066169A1 (es) * 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
US8324385B2 (en) * 2008-10-30 2012-12-04 Madrigal Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
WO2010086820A1 (en) * 2009-02-02 2010-08-05 Pfizer Inc. 4-amino-5-oxo-7, 8-dihydropyrimido [5,4-f] [1,4] oxazepin-6 (5h) -yl) phenyl derivatives, pharmaceutical compositions and uses thereof
WO2011121350A1 (en) 2010-04-01 2011-10-06 Astrazeneca Ab 4 -amino -7,8- dihydropyrimido [5, 4 - f] [1, 4] oxazepin- 5 ( 6h) - one based dgat1 inhibitors
DK2710013T3 (en) * 2011-05-20 2016-09-26 Glaxosmithkline Intellectual Property (No 2) Ltd New compounds such as diacylglycerol-acyltransferase inhibitors

Also Published As

Publication number Publication date
PT2922551T (pt) 2019-02-04
LT2922551T (lt) 2019-02-11
PH12015501109B1 (en) 2015-08-17
PE20150967A1 (es) 2015-06-25
DK2922551T3 (en) 2019-02-18
CA2892304A1 (en) 2014-05-30
EP2922551A1 (en) 2015-09-30
AU2013347843A1 (en) 2015-05-28
AU2013347843B2 (en) 2016-06-16
ES2708626T3 (es) 2019-04-10
CY1121426T1 (el) 2020-05-29
EP3492474A1 (en) 2019-06-05
BR112015011982A2 (pt) 2017-07-11
JP2016500109A (ja) 2016-01-07
SI2922551T1 (sl) 2019-05-31
ZA201503304B (en) 2016-05-25
PL2922551T3 (pl) 2019-06-28
KR20150087852A (ko) 2015-07-30
EP3492474B1 (en) 2021-08-11
MX363484B (es) 2019-03-21
ME03315B (me) 2019-10-20
RS58539B1 (sr) 2019-04-30
WO2014081994A1 (en) 2014-05-30
US20150322082A1 (en) 2015-11-12
SG11201503761WA (en) 2015-06-29
HK1214757A1 (zh) 2016-08-05
EA031114B1 (ru) 2018-11-30
CN104918620B (zh) 2017-06-09
CL2015001397A1 (es) 2015-08-28
MX2015006533A (es) 2015-08-06
PH12015501109A1 (en) 2015-08-17
NZ630436A (en) 2016-08-26
IL238835A0 (en) 2015-06-30
HUE042483T2 (hu) 2019-06-28
JP6279600B2 (ja) 2018-02-14
KR102176463B1 (ko) 2020-11-09
EP2922551A4 (en) 2016-04-27
EP2922551B1 (en) 2018-10-31
CA2892304C (en) 2021-03-30
BR112015011982A8 (pt) 2019-10-08
CN104918620A (zh) 2015-09-16
HRP20190099T1 (hr) 2019-04-19
EA201590982A1 (ru) 2015-11-30
IL238835B (en) 2019-07-31

Similar Documents

Publication Publication Date Title
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
MX2013008192A (es) Inhibidores de bace-2 para tratamiento de transtornos metabolicos.
MX356525B (es) Vectores de virus asociados con adeno (aav) para uso en terapia de genes de coroideremia.
PH12014502757B1 (en) Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
PH12016501654A1 (en) Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders
IN2013CN01340A (uk)
WO2014031928A3 (en) Heterocyclic modulators of hif activity for treatment of disease
EA024842B9 (ru) Соединения в качестве модуляторов протеинкиназы pi3k
MX343687B (es) Compuestos sulfonamida tricíclica y métodos para su fabricación y uso.
MX2015002669A (es) Metodos de administracion de tratamiento con pirfenidona.
PH12014502513A1 (en) Nampt inhibitors
MX2014013752A (es) Inhibidores de nampt.
MX2014008705A (es) Compuestos tricíclicos de sulfona y métodos para elaborarlos y utilizarlos.
IN2015DN01151A (uk)
MX2017004618A (es) Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades.
WO2014031933A3 (en) Heterocyclic modulators of hif activity for treatment of disease
MX2014008706A (es) Compuestos tricíclicos de sulfonamida y métodos para elaborarlos y usarlos.
GB2533454A (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
WO2014031936A3 (en) Heterocyclic modulators of hif activity for treatment of disease
MX337849B (es) Composiciones y metodos para inhibicion de la via jak.
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
HK1182015A1 (zh) 活性藥物化合物用於治療中樞神經系統病症的用途
WO2013119946A8 (en) Long chain base sphingosine kinase inhibitors
MX2015005732A (es) Compuestos tricíclicos y métodos para hacer y utilizar los mismos.